Articles tagged "Rejection"

2022 American Transplant Congress
Outcomes of a Standardized Antibody-Mediated Rejection (AMR) Treatment Protocol in Heart Transplant Recipients (HTR)
J. Lee, T. Sam, J. Van Zyl, S. Mckean, L. Fuller, N. Wilson, A. Dao, R. Gottlieb, S. Hall, R. Patel
Baylor University Medical Center, Dallas, TX
*Purpose: AMR in HTR portends poor clinical outcomes. Reported mortality range between 20-50%, with higher rates reported for late AMR occurring at least 1 year…
2022 American Transplant Congress
Study of the Composition of the Inflammatory Burden on a Cohort of 125 Rejections by Multiplex Immunofluorescence
A. Mobio¹, M. Eloudzeri², L. Morin¹, J. Duong Van Huyen³, D. Anglicheau¹, M. Rabant³
¹Kidney transplantation, Necker-Enfants Malades Hospital, Paris, France, ²U1151, INEM, Paris, France, ³Pathology, Necker-Enfants Malades Hospital, Paris, France
*Purpose: The exact composition of the inflammatory burden during kidney transplant rejection has not been studied on large cohorts. Moreover, the determinants and impact of…
2022 American Transplant Congress
The Use of Donor-Derived Cell-Free DNA in Female and Male Heart Transplant Recipients: A Sex-Specific Analysis of the Surveillance Heartcare Outcomes Registry
E. M. DeFilippis¹, Y. Fu², R. Burke², M. Deng³, M. Kamath⁴, L. Lourenco Jenkins², A. R. Vest⁵
¹Columbia University Irving Medical Center, New York, NY, ²CareDx, Brisbane, CA, ³David Geffen School of Medicine at UCLA, Los Angeles, CA, ⁴Ronald Reagan UCLA Medical Center, Los Angeles, CA, ⁵Tufts Medical Center, Boston, MA
*Purpose: To investigate sex-specific donor-derived cell-free DNA AlloSure (AS) levels during allograft quiescence and rejection after heart transplantation.*Methods: Sex-stratified data were obtained from the Surveillance…
2022 American Transplant Congress
TCMR in Late Kidney Transplant Biopsies Shows Less Molecular TCMR Activity and More Fibrosis Despite Persistence of Tubulitis and Interstitial Infiltrate
K. S. Madill-Thomsen¹, J. Reeve¹, P. Halloran¹, .. and the INTERCOMEX Study Group²
¹Alberta Transplant Applied Genomics Centre, Edmonton AB, AB, Canada, ²., ., AB, Canada
*Purpose: We studied the relationship between time post-transplant and molecular T cell-mediated rejection (TCMR) activity in a population of indication kidney transplant biopsies.*Methods: Updated rejection-based…
2022 American Transplant Congress
Noninvasive Biomarkers for Allograft Monitoring After Intestinal Transplantation: Promising Early Results from a Novel Peptide, REG3α
C. P. Smullin¹, R. S. Venick², E. A. Marcus², B. V. Naini³, D. G. Farmer⁴
¹David Geffen School of Medicine at University of California Los Angeles, Los Angeles, CA, ²Pediatrics, David Geffen School of Medicine at University of California Los Angeles, Los Angeles, CA, ³Pathology, David Geffen School of Medicine at University of California Los Angeles, Los Angeles, CA, ⁴Surgery, David Geffen School of Medicine at University of California Los Angeles, Los Angeles, CA
*Purpose: There is an urgent need for the discovery and application of noninvasive biomarkers to detect allograft rejection after intestinal transplantation (ITx). Calprotectin and citrulline…
2022 American Transplant Congress
Tocilizumab in Chronic Active Antibody-Mediated Rejection in Kidney Transplant Recipients: A Case Series
B. Boonpheng¹, R. Bakthavatsalam², C. D. Blosser¹, I. C. De Castro¹, I. Gimferrer³, Y. Ng¹, N. Leca¹
¹Nephrology, University of Washington, Seattle, WA, ²Surgery, University of Washington, Seattle, WA, ³Bloodworks Northwest, Seattle, WA
*Purpose: The optimal treatment for chronic active antibody-mediated rejection (ca-AMR) remains unclear. Tocilizumab (TCZ), a monoclonal antibody against IL-6, has been proposed in ca-AMR treatment…
2022 American Transplant Congress
The Addition of Bortezomib to a Rituximab Based Antibody Mediated Rejection Treatment Protocol in Lung Transplant
M. Galle, P. Stracener, K. Warrior, J. Lyons
Loyola University Medical Center, Maywood, IL
*Purpose: To evaluate the impact of antibody mediated rejection (AMR) treatment with rituximab combined with bortezomib vs. rituximab alone on patient survival, graft survival, and…
2022 American Transplant Congress
Using a Unique Repository of Pancreas Transplant Biopsies to Validate the Tissue Common Response Module (tCRM) Score as a Tool to Assess the Severity of Pancreas Transplant Rejection
Y. Kelly¹, A. Zarinsefat¹, R. Meier², M. Sarwal¹, P. Stock¹, Z. Laszik¹, T. Sigdel¹
¹University of California, San Francisco, San Francisco, CA, ²University of Maryland Medical Center, Baltimore, MD
*Purpose: Analysis of transcriptional data from kidney, heart, liver, and lung transplant rejection led to development of the tissue Common Response Module (tCRM) score based…
2022 American Transplant Congress
Tracking of Donor Reactive T Cell Clones Can Be Used to Diagnose or Even Predict Kidney Transplant Rejection
J. M. Mathew¹, Y. Sambandam¹, M. Kandpal¹, J. He¹, G. Perottino¹, B. Banbury², P. Fields², L. Gallon¹, J. R. Leventhal¹
¹Northwestern University, Chicago, IL, ²Adaptive Biotechnologies, Seattle, WA
*Purpose: Transplant (Tx) rejection currently requires an invasive biopsy for diagnosis. We have tested if serial quantitation of donor reactive T cell clones (DRTC) can…
2022 American Transplant Congress
Prospective Evaluation of Donor-Derived Cell-Free DNA (dd-cfDNA) in Monitoring Response to Anti-Rejection Treatment in Kidney Transplant Recipients with Indication Biopsy
L. Benning¹, A. Fink², F. Kälble¹, C. Speer¹, C. Nusshag¹, M. Zeier¹, C. Süsal³, C. Morath¹, T. Tran²
¹Department of Nephrology, University Hospital Heidelberg, Heidelberg, Germany, ²Transplantation Immunology, Institute of Immunology, University Hospital Heidelberg, Heidelberg, Germany, ³Transplant Immunology Research Center of Excellence, Koç University Hospital, Istanbul, Turkey
*Purpose: Donor-derived cell-free DNA (dd-cfDNA) is a marker of allograft injury in kidney transplant recipients (KTR). Little is known about the possible use of dd-cfDNA…